期刊文献+

高效液相色谱法测定人血浆中兰索拉唑浓度 被引量:2

Determination of lansoprazole in human plasma by HPLC
下载PDF
导出
摘要 目的建立测定人血浆中兰索拉唑浓度的高效液相色谱方法。方法血浆样品经二氯甲烷和乙醚的混合提取液提取后,以乙腈:0.05mol/L磷酸二氢氨溶液(pH7.0,35:65)为流动相,经PAPCELLPAK-C18色谱柱分离,于285nm波长处检测。结果兰索拉唑浓度在0.025~2.0μg/mL范围内线性关系良好,最低检测浓度为0.025μg/mL;低、中、高3个浓度的提取回收率均大于74%,日内、日间相对标准差低于8.22%。结论本方法准确、快速,可满足临床药代动力学研究的要求。 Objective An I-IPLC method was established for determination of lansoprazole in human serum. Methods Serum protein was precipitated with trichloroacetic acid. The analysis was conducted with a Diarnonsil-C18 (4. 6 mm× 150 mm,5 um)column, acetonitrile -0. 05 moVL citric buffer(pH4.0,18:82) was served as mobile phase, the detecting wavelengh was at 310 am. Results The linear range lansoprazole was 0. 025 - 2. 0 ug/mL ( n = 3, r = 0. 997 7)and the average recovery was 74. 0% -81.5% at three different concentrations. The RSD of intra- and interday were less than 8. 22%. Conclusion This method is suitable for the phafrnacokinetic study of lansoprazole.
出处 《实用药物与临床》 CAS 2009年第1期28-29,共2页 Practical Pharmacy and Clinical Remedies
基金 辽宁省科学技术厅重大项目资助 项目编号:2006226006
  • 相关文献

参考文献5

共引文献45

同被引文献23

  • 1杨杰.高效液相色谱仪检测器进展及其在药物分析中的应用[J].实用药物与临床,2007,10(3):187-188. 被引量:11
  • 2罗继名,张永东,肖云彬,林杰,李嫩祥.高效液相色谱法测定人血浆中司帕沙星药物浓度[J].实用药物与临床,2007,10(4):252-253. 被引量:3
  • 3Sun L, Liang C, Shirazian S, et al. Discovery of 5- [ 5-fluoro-2-oxo- 1,2-dihydroindol-( 3 Z ) -ylidenemethyl ] -2,4-dimethyl-1 H-pyrrole- 3-carboxylic acid (2-diethylaminoethyl)amide, a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor receptor tyrosine kinase. J Med Chem, 2003,46 ( 7 ) : 1116-1119.
  • 4Goodman VL, Rock EP, Dagher R, et al. Approval summary:sunitinib for the treatment of imatinib refractory or intolerant gastro-intestinal stromal tumors and advanced renal cell carcinoma. Clin Cancer Res, 2007,13 ( 5 ) : 1367 -1373.
  • 5Ikeda K, Ikawa K, Ikeda A, et al. A simple and rapid determination of biapenem in plasma by high-performance liquid chromatography. J Chromatogr B Analyt Technol Biomed Life Sci, 2006,844 ( 1 ) : 148-152.
  • 6Gomy M, Rtihm S, Laer S, et al. Pharmacogenomic adaptation of antiretroviral therapy: overcoming the failure of lopinavir in an African infant with CYP2D6 ultrarapid metabolism. Eur J Clin Pharmaeol, 2010,66( 1 ) : 107-108.
  • 7Rodamer M, Elsinghorst PW, Kinzig M, et al. Development and validation of a liquid chromatography/tandem mass spectrometry procedure for the quantification ofsunitinib ( SUl1248 ) and its active metabolite, N-desethyl sunitinib (SU12662), in human plasma: application to an explorativestudy. J Chromatogr B Analyt Teehnol Biomed Life Sci,2011,879(11-12) :695-706.
  • 8Najm WI. Peptic ulcer disease [ J ]. Prim Care, 2011,38 : 383- 394.
  • 9Lundell L. Acid secretion and gastric surgery [ J ]. Dig Dis, 2011,29:487-490.
  • 10Shiotani A,Kamada T,Kusunoki H,et al. Proton pump inhibi- tor H2 receptor antagonist [ J ]. Nihon Rinsho, 2011,69 : 1032- 1038.

引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部